{"id":"cs-sg","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without access to detailed pharmacological data on this specific combination code, the exact mechanism cannot be reliably determined. CS+SG appears to be a proprietary combination designation from Tedec-Meiji Farma, and the individual components' mechanisms would need to be identified to provide accurate mechanistic detail.","oneSentence":"CS+SG is a combination therapy that likely combines two active pharmaceutical components to enhance therapeutic efficacy through complementary mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:08:03.362Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT01893905","phase":"PHASE3","title":"Efficacy and Safety of a New Formulation of Chondroitin Sulfate and Glucosamine Sulfate to Treat Knee Osteoarthritis","status":"COMPLETED","sponsor":"Tedec-Meiji Farma, S.A.","startDate":"2013-06","conditions":"Knee Osteoarthritis","enrollment":158}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Chondroitin sulfate+glucosamine sulfate"],"phase":"phase_3","status":"active","brandName":"CS+SG","genericName":"CS+SG","companyName":"Tedec-Meiji Farma, S.A.","companyId":"tedec-meiji-farma-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}